India accounts for 20% of the global supply of generic medicines CAGR rose by 30% in the last bull run between 2009 and 2016 *** One sector that was heavily mauled in the recent sell-off is pharma. Hence, the stocks in this space appear attractively priced. Pharma is considered a defensive sector and could be a perfect pill to ride the volatile markets. India’s pharmaceutical industry ranks third globally in terms of production volume. According to the annual report released in 2023 by the Department of Pharmaceuticals, which falls under the Ministry of Chemicals and Fertilisers, the total annual turnover of pharmaceuticals in the fiscal year 2021-22 was Rs 3,44,125 crore. Moreover, the country is the largest producer of generic medicines. It manufactures about 60,000 different generic brands across 60 therapeutic categories and accounts for 20 per cent of the global supply of generics. No wonder, during its last bull run between 2009 and 2016, the S&P BSE Healthcare Index jumped nearly six-fold, resulting in an impressive compounded annual growth rate (CAGR) of nearly 30...